About: Jacques Cadranel

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Jacques Cadranel Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Cadranel, Jacques Cadranel, Jacques Cadranel, Jacques Cadranel, Jacques
bnf-onto:FRBNF	12710892(xsd:integer)
preferred label	Cadranel, Jacques
name	Jacques Cadranel
dbpedia-owl:citizenship	http://sws.geonames.org/3017382/
Language	http://lexvo.org/id/iso639-3/fra
isni:identifierValid	000000043968266X
Given name	Jacques
familyName	Cadranel
has biographical i...tion (Deprecated)	Directeur d'une thèse d'exercice de médecine à l'Université de Paris (2019-....) (en 2020)
note	Médecin pneumologue, Hôpital Tenon
gender	male
ORCID iD	0000-0003-2446-2923
Scopus ID	7102514445
is sameAs of	Cadranel, Jacques Cadranel, Jacques Cadranel, Jacques Cadranel, Jacques
is Thesis advisor of	http://www.sudoc.fr/049497847/id http://www.sudoc.fr/089425731/id http://www.sudoc.fr/041910583/id http://www.sudoc.fr/041841166/id http://www.sudoc.fr/081589301/id http://www.sudoc.fr/227327616/id http://www.sudoc.fr/060563133/id http://www.sudoc.fr/04124866X/id http://www.sudoc.fr/059986301/id http://www.sudoc.fr/24682770X/id Rôle des polynucléaires neutrophiles dans la progression aérogène des adénocarcinomes pulmonaires http://www.sudoc.fr/233192247/id http://www.sudoc.fr/253868971/id http://www.sudoc.fr/053686896/id http://www.sudoc.fr/257698183/id
is Praeses of	http://www.sudoc.fr/190675446/id http://www.sudoc.fr/190154667/id
is Author of	http://www.sudoc.fr/196682770/id http://www.sudoc.fr/001156799/id http://www.sudoc.fr/042996473/id Sarcoidosis in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort Nebulised liposomal-amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis : a randomised, multicentre trial Randomised trial of first-line bronchial artery embolisation for non-severe haemoptysis of mild abundance Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal? Brief report of Anti-PD1 in HIV setting: relevant and breaking results in first-line Non Small Cell Lung Cancer therapy Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry Real-life experience of ceritinib in crizotinib-pretreatedadvanced non-small cell lung cancer patients Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 ANCA-associated lung fibrosis: analysis of 17 patients. Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients. No impact of passive smoke on the somatic profile of lung cancers in never-smokers How to reduce lung cancer mortality among people living with HIV? From smoking cessation to radiological screening Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study 1,25 (OH) 2d3 médiateur endocrine et paracrine au cours des granulomatoses pulmonaires Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study Rituximab for auto-immune alveolar proteinosis, a real life cohort study An expert statment on clinical considerations before treating NTM lung infection Efficacy of nebulized liposomal amphotericin B in the treatment of ABPA in an HIV/HBV co-infected man: Case report and literature review https://serval.unil.ch/notice/serval:BIB_EA0BC4C676A6#id Improvement of Symptomatic Human Immunodeficiency Virus-Related Lymphoid Interstitial Pneumonia in Patients Receiving Highly Active Antiretroviral Therapy Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP) Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: a therapeutic trap? Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial CT Imaging Assessment of Response to Treatment in Chronic Pulmonary Aspergillosis Phenotyping chronic pulmonary aspergillosis by cluster analysis Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study Lorlatinib for advanced ALK and ROS1+non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort. Professional exposure to goats increases the risk of pneumonic-type lung adenocarcinoma: results of the IFCT-0504-Epidemio study. Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patients IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort No evidence for a pathogen associated with pulmonary MALT lymphoma: a metagenomics investigation Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients RSPH3 Mutations Cause Primary Ciliary Dyskinesia with Central-Complex Defects and a Near Absence of Radial Spokes https://archive-ouverte.unige.ch/unige:47106#id A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting―IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms Clinical Relevance of EGFR - or KRAS - mutated Subclones in Patients With Advanced Non–small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2) Nivolumab-refractory patients with advanced non-small-cell lung cancer Impact of COVID-19 and lockdowns on pulmonary embolism in hospitalized patients in France: a nationwide study Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities Routine molecular profiling of cancer: results of a one-year nationwide program of the French CooperativeThoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients. Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial Erratum to ‘‘French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Franc¸aise’’ [Rev. Mal. Respir. 30 (10) 879—902] http://www.sudoc.fr/041855914/id Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients La réintroduction de chimiothérapie est-elle faisable au cours du traitement du cancer pulmonaire non à petites cellules de stade avancé ? Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Élaborées par le centre national de référence et les centres de compétence pour les maladies pulmonaires rares sous l’égide de la Société de pneumologie de langue française [French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française]

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software